Trial | Model | % Delta | |
---|---|---|---|
Age group 6–12 weeks | |||
Clinical episodes | |||
Control | 3718 | 3798 | +2.2 |
Vaccine | 4487 | 4802 | +7.0 |
Severe episodes (% of clinical episodes) | |||
Control (%) | 2.76 | 2.70 | −2.2 |
Vaccine (%) | 2.91 | 3.58 | +23 |
Age group 5–17 months | |||
Clinical episodes | |||
Control | 5409 | 4967 | −8.2 |
Vaccine | 5133 | 4154 | −19 |
Severe episodes (% of clinical episodes) | |||
Control (%) | 2.20 | 1.96 | −10.9 |
Vaccine (%) | 2.27 | 2.69 | +18.5 |